A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 21 Feb 2017 Status changed from active, no longer recruiting to completed.
- 17 Jun 2016 Planned End Date changed from 1 Mar 2017 to 1 Feb 2017.
- 17 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History